Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2022-09-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
上海荣正投资咨询股份有限公司关于无锡祥生医疗科技股份有限公司2022年限制性股票激励计划（草案）之独立财务顾问报告
Regulatory Filings Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the "2022 Restricted Stock Incentive Plan (Draft)" of Wuxi Xiangsheng Medical Technology Co., Ltd. It contains detailed sections on definitions, statements, assumptions, main content of the restricted stock incentive plan, including scope, allocation, pricing, vesting conditions, and independent financial advisor opinions on compliance with laws and regulations. The document is a comprehensive advisory report on a stock incentive plan, which is a form of equity compensation plan. It is not an announcement of voting results, not a proxy solicitation, not a remuneration report, nor a general regulatory filing. It is not a financial report like an annual or interim report, nor an earnings release. It is a specialized report providing an independent financial advisor's opinion on the stock incentive plan's compliance and feasibility. This type of document fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure document related to equity incentive plans and compliance, but does not fit other more specific categories like remuneration information or proxy solicitation. The document length is substantial and contains detailed analysis and opinions, not just an announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2022-09-30 Chinese
祥生医疗关于召开2022年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 second extraordinary general meeting of shareholders for Wuxi Xiangsheng Medical Technology Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and instructions for shareholders. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. The document length is 3196 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-09-30 Chinese
祥生医疗关于独立董事公开征集委托投票权的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is an announcement by an independent director of Wuxi Xiangsheng Medical Technology Co., Ltd. regarding the public solicitation of proxy voting rights for the company's 2022 second extraordinary general meeting of shareholders. It details the solicitation process, the voting agenda related to a restricted stock incentive plan, the independent director's background and voting opinion, and instructions for shareholders to submit proxy voting authorizations. The document does not contain financial statements or results but is a formal announcement related to shareholder voting rights and proxy solicitation for a specific shareholders' meeting. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-09-30 Chinese
祥生医疗2022年限制性股票激励计划首次授予激励对象名单
Capital/Financing Update Classification · 95% confidence The document is a list of recipients for a restricted stock incentive plan for the year 2022, including allocation details of restricted stock units to various categories of employees. It is a specific announcement related to equity compensation rather than a full financial report or earnings release. The document is short (444 characters) and focuses on stock incentive allocation, which aligns with capital or financing updates. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-09-30 Chinese
祥生医疗2022年限制性股票激励计划（草案）摘要公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a 2022 restricted stock incentive plan (股权激励计划) for Wuxi Xiangsheng Medical Technology Co., Ltd. It includes specifics about the stock incentive plan such as the number of shares, pricing, vesting conditions, performance targets, legal compliance, and procedures for granting and vesting restricted stock. The content focuses on the company's equity incentive plan, which is a form of compensation and capital structure update involving issuance of shares to employees and management. This type of document is not a financial report, earnings release, or management discussion, but rather an announcement related to capital changes and financing activities due to the issuance of restricted stock. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed plan terms, not just a brief announcement or summary, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2022-09-30 Chinese
祥生医疗第二届监事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 14th meeting of the 2nd Supervisory Board of Wuxi Xiangsheng Medical Technology Co., Ltd. It details the approval of a 2022 restricted stock incentive plan, its implementation assessment methods, and verification of the initial list of incentive recipients. The document includes voting results and mentions that these resolutions will be submitted to the 2022 second extraordinary shareholders' meeting for approval. The content is procedural and governance-related, focusing on board/supervisory decisions and internal approvals rather than financial results or reports. It is not a full financial report, earnings release, or regulatory filing of financial data. It is also not a proxy solicitation or voting results announcement. The document fits best under Board/Management Information (MANG) as it relates to supervisory board decisions and governance matters regarding stock incentive plans.
2022-09-30 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.